An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer

Inclusion Criteria: * Age\>18 * Histologically proven epithelial ovarian cancer * ECOG 0-1 * Partially platinum sensitive relapsed ovarian cancer: platinum-free interval 6 -12 months * With 1-2 or more cycles on trabectedin treatment at the recommended dose of 1.1mg/m2 q3w 3hr infusion in combination of PLD at 30mg/ml with appropriate pre-medication * Prior treatment with 1 or more chemotherapy regimen Exclusion Criteria: * Platinum resistant disease: PFI \< 6 months (progression within six months after first-line platinum-based chemotherapy) * Unwilling or unable to have a central venous catheter * Patients with hepatic impairment (Patients with elevated bilirubin) * Patients with renal impairment (Patients with serum creatinine \>1.5 mg/dL) * Patients with hematologic impairment (baseline neutrophil counts of less than 1,500 cells/mm3 and platelets count of less than 100,000 cells/mm3) * Patients with serious impaired cardiac function (patients with cardiac disease and with reduction of the QRS complex) * AIDS-related Kaposi's sarcoma * Lactation or pregnancy